Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof

Details for Australian Patent Application No. 2005227907 (hide)

Owner The Trustees of Columbia University in the City of New York

Inventors Deng, Shixian; Cheng, Zhen Zhuang; Marks, Andrew R.; Landry, Donald W.

Agent Spruson & Ferguson

Pub. Number AU-B-2005227907

PCT Pub. Number WO2005/094457

Priority 10/809,089 25.03.04 US

Filing date 22 March 2005

Wipo publication date 13 October 2005

Acceptance publication date 16 December 2010

International Classifications

C07D 281/06 (2006.01) Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61K 31/554 (2006.01) - having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem

A61P 9/06 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

16 November 2006 PCT application entered the National Phase

  PCT publication WO2005/094457 Priority application(s): WO2005/094457

16 December 2010 Application Accepted

  Published as AU-B-2005227907

14 April 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005227916-Methods for reducing the range in concentrations of analyte species in a sample

2005227905-Inkjet print head synchronous serial output for data integrity